Tracking tumor evolution during the first-line treatment in brain glioma via serial profiling of cell-free tumor DNA from tumor in situ fluid

Frontiers in Oncology

Oncology

Ziyue Zhang¹  Yushuai Gao¹  Guangzhong Guo¹  Sensen Xu¹  Jie Mei²  Chaojie Bu³  Zhiyuan Sheng⁴  Zhongcan Chen⁴  Juha Hernesniemi⁴  Xingyao Bu⁴  Ajmal Zemmar⁴  Liyuan Xing⁵ 

[1] Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China;Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China;Department of Nursing, Henan Provincial People’s Hospital, Zhengzhou, China;Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China;Department of Psychological Medicine, Henan Provincial People’s Hospital, Zhengzhou, China;Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China;Juha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China;Department of Nursing, Henan Provincial People’s Hospital, Zhengzhou, China;

关键词: glioma;    cell-free tumor DNA;    tumor evolution;    in situ;    precision medicine;   

DOI  :  10.3389/fonc.2023.1238607

 received in 2023-06-12, accepted in 2023-09-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

ObjectiveTumor in situ fluid (TISF) refers to the fluid within surgical cavities of glioma. Several studies preliminarily proved the value of cell-free tumor DNA (cf-tDNA) from TISF in the dynamic characterization of the glioma genome. Here, we assessed the potential utility of TISF cf-tDNA in broad aspects of tumor evolution under therapeutic pressure.MethodsThis study was conducted under an Institutional Review Board-approved protocol at Henan Provincial People’s Hospital (China). Cf-tDNA samples were sequenced with a designed 68-gene panel. A total of 205 cf-tDNA samples from 107 patients were studied. The clinical relevance of serial cf-tDNA profiling during the postoperative course was analyzed.ResultsAt least one tumor mutations were detected in 179/205 (87.3%) TISF cf-tDNA samples. Serial cf-tDNA was complementary to molecular residual disease and to initial tumors. Serial cf-tDNA revealed the selection of pre-existing mismatch repair-deficient cells by temozolomide as a resistant mechanism. Cf-tDNA parameters during treatment were predictive of recurrence, and serial cf-tDNA monitoring had diagnostic value for early recurrence. A total of 223 potentially actionable genomic alterations were assessed in cf-tDNA samples, wherein 78% were not found in any tumor tissue.ConclusionsIn conclusion, serial TISF cf-tDNA profiling is valuable in tracking the tumor evolution of glioma during treatment and may be a feasible non-invasive option for monitoring glioma in future prospective studies and clinical practice.

【 授权许可】

Unknown   
Copyright © 2023 Sheng, Bu, Mei, Xu, Zhang, Guo, Gao, Xing, Chen, Hernesniemi, Zemmar and Bu